Effect of BIM on advanced non-small cell lung cancer
10.3969/j.issn.1000-8179.2017.21.652
- VernacularTitle:BIM在晚期非小细胞肺癌治疗中的作用
- Author:
ZHOU FENGGE
1
;
FENG ALEI
;
DAI HONGHAI
;
HAN JUNQING
Author Information
1. 山东大学附属省立医院肿瘤研究治疗中心 济南市250021
- Keywords:
BIM;
EGFR;
ALK;
NSCLC;
targeted therapy
- From:
Chinese Journal of Clinical Oncology
2017;44(21):1095-1099
- CountryChina
- Language:Chinese
-
Abstract:
Lung cancer displays the highest morbidity and mortality worldwide. Non-small cell lung cancer (NSCLC) is the most com-mon type of lung cancer. In-depth research was performed on the pathogenesis and biological behavior of lung cancer and the im-provement of genetic testing level. The discovery of drugs targeting epidermal growth factor receptor and anaplastic lymphoma kinase plays a significant role in individual treatment of advanced NSCLC. BIM is a protein in the Bcl-2 family that promotes apoptosis, which leads to cell death. The BIM expression level and polymorphism can influence the therapeutic effect of targeted therapy and chemo-therapy on advanced NSCLC. Therefore, this review summarizes BIM and its effects on targeted therapy and chemotherapy for ad-vanced NSCLC.
